Clinical Trial

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Name: A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma — clinical trial record (NCT07681596)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Trial Details

NCT Number	NCT07681596
Lead Sponsor	AstraZeneca
Conditions	Relapsed or Refractory Multiple Myeloma
Enrollment	101 participants
Start Date	2026-07-09
Primary Completion	2029-10-30 (estimated)
Study Completion	2029-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-02